Clinical Research Directory

Inclusion Criteria: * Adults ≥18 years of age * Meet criteria for CRSwNP as defined by ICAR-21 * 2 out of 4 cardinal symptoms for ≥12 weeks * Visible evidence of inflammation on endoscopy or imaging * Bilateral visible nasal polyps ≥1 in each nasal cavity (0-4 scale each side) * Olfaction score ≥1 (0-3 scale) * Candidate for treatment with dupilumab for CRSwNP * Elected to proceed with dupilumab for treatment of CRSwNP Exclusion Criteria: * Prior use of dupilumab * Previous treatment with another biologic medication for CRSwNP or asthma within 6 months * Any nasal or sinus surgery within the last 3 months * Oral corticosteroid use within the last 1 month * Current pregnancy, breast-feeding, or plan to become pregnant during next 3 months * Presence of antrochoanal nasal polyps; acute rhinosinusitis; upper respiratory infection; * Allergic granulomatous angiitis/eosinophilic granulomatosis with polyangiitis; * Granulomatosis with polyangiitis; cystic fibrosis; Young syndrome; * Kartagener syndrome; or dyskinetic cilia syndrome * Poorly controlled asthma